TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8936546

Group type: EXPERIMENTAL
Intervention: Caudal bupivicaine (0.25%) 2 mg.kg-1 before surgical incision, followed by caudal normal saline infused at the same volume after surgical incision.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Caudal saline before surgical incision followed by caudal bupivicaine (0.25%) infused 15 min after surgical incision.
Number of subjects: 10
Study: 1448244

Group type: EXPERIMENTAL
Intervention: Closure of Camper fascia with absorbable suture
Number of subjects: 438

Group type: COMPARATOR
Intervention: No closure of Camper fascia
Number of subjects: 438
Study: 6387197

Group type: EXPERIMENTAL
Intervention: Timolol maleate, 20 to 30 mg/day
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 31740871

Group type: EXPERIMENTAL
Intervention: Papillary thyroid cancer (group 1)
Number of subjects: 90
Study: 30310273

Group type: EXPERIMENTAL
Intervention: GFF MDI 18/9.6 μg
Number of subjects: 1756

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 1756

Group type: COMPARATOR
Intervention: GP MDI 18 μg
Number of subjects: 1756

Group type: COMPARATOR
Intervention: FF MDI 9.6 μg
Number of subjects: 1756
Study: 25756231

Group type: EXPERIMENTAL
Intervention: Slackline training (3 times per week for 6 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no slackline training)
Number of subjects: 32
Study: 26882607

Group type: EXPERIMENTAL
Intervention: External use of Shengji Ointment (SO), exchange once every 24 h for 21 days
Number of subjects: 440

Group type: COMPARATOR
Intervention: External use of Votalin, exchange once every 24 h for 21 days
Number of subjects: 440
Study: 22652506

Group type: EXPERIMENTAL
Intervention: 20 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 mg/day meso‐zeaxanthin (MZ), 10 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 17 mg/day meso‐zeaxanthin (MZ), 3 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Number of subjects: 31
Study: 20919513

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Number of subjects: 0
Study: 18806063

Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15704026

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 100
Study: 12232543

Group type: EXPERIMENTAL
Intervention: tianeptine (37.5 mg)
Number of subjects: 212

Group type: COMPARATOR
Intervention: sertraline (50 mg)
Number of subjects: 212
Study: 10091827

Group type: EXPERIMENTAL
Intervention: abciximab (group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 75
Study: 7749833

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1979463

Group type: EXPERIMENTAL
Intervention: Moditen-depot
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine maintenance therapy
Number of subjects: 0
Study: 6311785

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 g) administered by iv rapid injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 g) administered by im injection
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Probenecid (1 g) administered one hour before ceftizoxime
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no probenecid)
Number of subjects: 12
Study: 31249252

Group type: EXPERIMENTAL
Intervention: dexmedetomidine 10 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: dexmedetomidine 5 μg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study: 30373659

Group type: EXPERIMENTAL
Intervention: Arthroscopic osteochondroplasty with or without labral repair
Number of subjects: 220

Group type: COMPARATOR
Intervention: Arthroscopic lavage of the hip joint
Number of subjects: 220
Study: 26945402

Group type: EXPERIMENTAL
Intervention: hMG (150-225 IU) and MPA (10 mg/d) administered simultaneously starting on cycle day 3
Number of subjects: 120

Group type: COMPARATOR
Intervention: Short protocol (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: hMG + MPA
Number of subjects: 120
Study: 24284453

Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Gait training without RAS (Control)
Number of subjects: 16
Study: 23265030

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 84
Study: 21094811

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) therapy for 3 months
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) therapy
Number of subjects: 75
Study: 17995484

Group type: EXPERIMENTAL
Intervention: Threat information about novel animals
Number of subjects: 26

Group type: COMPARATOR
Intervention: Positive information about novel animals
Number of subjects: 26

Group type: COMPARATOR
Intervention: No information about novel animals
Number of subjects: 26
Study: 16985503

Group type: EXPERIMENTAL
Intervention: Alcohol (0, 0.02-0.04 mg%, or 0.06-0.08 mg%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 15625770

Group type: EXPERIMENTAL
Intervention: Amlodipine plus HRT
Number of subjects: 29

Group type: COMPARATOR
Intervention: Amlodipine alone
Number of subjects: 29
Study: 11106138

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8772580

Group type: EXPERIMENTAL
Intervention: AC137 (100 micrograms/h, n = 1; 50 micrograms/h, n = 6)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: AC137
Number of subjects: 7
Study: 1344238

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 1.5 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline (N/S) 0.1 ml/kg (control group)
Number of subjects: 50
Study: 6141161

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 74

Group type: COMPARATOR
Intervention: 1 mg lorazepam
Number of subjects: 74

Group type: COMPARATOR
Intervention: 7.5 mg clorazepate
Number of subjects: 74

Group type: COMPARATOR
Intervention: 15 mg clorazepate
Number of subjects: 74
Study: 29464411

Group type: EXPERIMENTAL
Intervention: Active head impulse VOR adaptation training for 15 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Passive head impulse VOR adaptation training for 15 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active VOR training during two single 60-min interval sessions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exposure to a de-adaptation stimulus
Number of subjects: 10
Study: 28811748

Group type: EXPERIMENTAL
Intervention: Moderate intensity (70% peak power) cycling exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ratings of perceived exertion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coordination of stress response pathways (α‐amylase vs cortisol)
Number of subjects: 20
Study: 26278823

Group type: EXPERIMENTAL
Intervention: IVDU-MV
Number of subjects: 172

Group type: COMPARATOR
Intervention: MV
Number of subjects: 172
Study: 22957889

Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI) with raw hen's egg emulsion for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (egg-free diet for 6 months)
Number of subjects: 20
Study: 21477315

Group type: EXPERIMENTAL
Intervention: Systematic preoperative instruction
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study: 18176828

Group type: EXPERIMENTAL
Intervention: Marginal sutured incision (Group 1, n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Open left incision (Group 2, n=45)
Number of subjects: 90
Study: 16899964

Group type: EXPERIMENTAL
Intervention: Collaborative care model with training for GPs and psychiatric consultation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Care as usual by the GP
Number of subjects: 81
Study: 12928692

Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg twice daily (b.i.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 10822211

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 44
Study: 8853772

Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid 500 mg and chenodeoxycholic acid 500 mg per day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Bile acids (ursodeoxycholic acid and chenodeoxycholic acid)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bile acids and Placebo
Number of subjects: 102
Study: 1633897

Group type: EXPERIMENTAL
Intervention: Active immunization with husband's or third party leukocytes (44 patients)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (27 patients)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy in pregnancy (18 patients)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combined study groups (anticardiolipin antibody-positive vs. negative)
Number of subjects: 89
Study: 6385838

Group type: EXPERIMENTAL
Intervention: Furazolidone (100 mg four times daily for 5 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ampicillin (500 mg four times daily for 5 days)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 94
Study: 31929250

Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 80

Group type: COMPARATOR
Intervention: epsilon‐amino‐caproic acid
Number of subjects: 80
Study: 31376274

Group type: EXPERIMENTAL
Intervention: MyPlan 2.0 intervention (5 sessions, 1 week apart)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 117
Study: 28566122

Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation during the first days of life
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard nutrition (control group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standardized weekly exchange of nasogastric feeding tubes
Number of subjects: 12
Study: 26424102

Group type: EXPERIMENTAL
Intervention: 8-week health-promotion intervention
Number of subjects: 548
Study: 24418693

Group type: EXPERIMENTAL
Intervention: Cisplatin/gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed
Number of subjects: 0
Study: 23040713

Group type: EXPERIMENTAL
Intervention: Cerebral embolization after CAS for asymptomatic carotid stenosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cerebral embolization after CAS for symptomatic carotid stenosis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: New acute cerebral emboli detected with DW‐MRI in asymptomatic patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: New acute cerebral emboli detected with DW‐MRI in symptomatic patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ipsilateral DW‐MRI lesions in asymptomatic patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ipsilateral DW‐MRI lesions in symptomatic patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total DW‐MRI lesions in asymptomatic patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total DW‐MRI lesions in symptomatic patients
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30-day stroke-death rate
Number of subjects: 40
Study: 19132604

Group type: EXPERIMENTAL
Intervention: Post-film processing with cognitive load during suppression
Number of subjects: 120

Group type: COMPARATOR
Intervention: No-suppression control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All experimental groups
Number of subjects: 120
Study: 18089377

Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) (3 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study: 15655272

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pravastatin 10 mg
Number of subjects: 16
Study: 11531666

Group type: EXPERIMENTAL
Intervention: Xenon sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol sedation
Number of subjects: 0
Study: 15251771

Group type: EXPERIMENTAL
Intervention: Micronized glyburide (sulfonylurea)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8350218

Group type: EXPERIMENTAL
Intervention: Whey hydrolysate formula (n = 25)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Whey-predominant formula (n = 20)
Number of subjects: 45
Study: 3523550

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0
Study: 29692287

Group type: EXPERIMENTAL
Intervention: Automated analysis of disorganized speech using Coh-Metrix 3.0
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Automated analysis of disorganized speech
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined automated analysis and clinician-rated measures
Number of subjects: 81
Study: 29255175

Group type: EXPERIMENTAL
Intervention: 0800 hours meal
Number of subjects: 20
Study: 26621156

Group type: EXPERIMENTAL
Intervention: 50 mg/d lisdexamfetamine dimesylate (LDX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70 mg/d lisdexamfetamine dimesylate (LDX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 mg/d lisdexamfetamine dimesylate (LDX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24449770

Group type: EXPERIMENTAL
Intervention: Piperaquine with concomitant food
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piperaquine without concomitant food
Number of subjects: 30
Study: 22964730

Group type: EXPERIMENTAL
Intervention: Peritoneal irrigation with a minimum of 500 mL normal saline
Number of subjects: 220

Group type: COMPARATOR
Intervention: Suction only
Number of subjects: 220
Study: 19686914

Group type: EXPERIMENTAL
Intervention: Coronectomy (case group, n = 102)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Extraction (control group, n = 118)
Number of subjects: 220
Study: 17454698

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Smokers with a past history of MDD
Number of subjects: 7

Group type: COMPARATOR
Intervention: Antidepressant treatment
Number of subjects: 7
Study: 15455256

Group type: EXPERIMENTAL
Intervention: tolterodine ER 4 mg once daily
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: oxybutynin 3 mg three times daily
Number of subjects: 293

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 293
Study: 12693431

Group type: EXPERIMENTAL
Intervention: Pay condition
Number of subjects: 97

Group type: COMPARATOR
Intervention: No Pay condition
Number of subjects: 97
Study: 10204597

Group type: EXPERIMENTAL
Intervention: Female donors, young donors, first-time donors, low-weight donors, and donors with low predonation blood pressure
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Age, weight, and donation status (first-time or repeat donor)
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Sex, predonation blood pressure, and predonation pulse
Number of subjects: 1890
Study: 8833935

Group type: EXPERIMENTAL
Intervention: CRF patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controls (healthy people with normal renal function)
Number of subjects: 25
Study: 2376265

Group type: EXPERIMENTAL
Intervention: Clinical photographic records
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no photographic records)
Number of subjects: 29
Study: 7031516

Group type: EXPERIMENTAL
Intervention: 60 mg/day bromopride for 15 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31161388

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST-PD) for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 76
Study: 28181675

Group type: EXPERIMENTAL
Intervention: Phytotherapeutic intervention (containing turmeric, resveratrol, green tea, and broccoli sprouts) for 12 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 22
Study: 24870446

Group type: EXPERIMENTAL
Intervention: LAI risperidone (LAI‐R)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Oral SGAs
Number of subjects: 305
Study: 24095230

Group type: EXPERIMENTAL
Intervention: Cheilectomy and microfracture procedure (Group A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cheilectomy and dorsal crescentic osteotomy (Group B)
Number of subjects: 14
Study: 21419437

Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic partial adrenalectomy
Number of subjects: 212

Group type: COMPARATOR
Intervention: Retroperitoneoscopic total adrenalectomy
Number of subjects: 212
Study: 18514614

Group type: EXPERIMENTAL
Intervention: Self-help cognitive behavioral treatment with minimal therapist contact
Number of subjects: 21

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 21
Study: 17596915

Group type: EXPERIMENTAL
Intervention: 20 mg dihydrexidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12929472

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (including angiotensin-converting enzyme inhibitors and angiotensin receptor blockers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of antihypertensive agents with diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blockade of the renin-angiotensin system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of angiotensin-converting enzyme inhibitor and diuretic as first-line treatment
Number of subjects: 0
Study: 11006432

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich, protein-poor food (CR/PP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Protein-rich, carbohydrate-poor (PR/CP) diet
Number of subjects: 45
Study: 8650997

Group type: EXPERIMENTAL
Intervention: Low‐energetic extracorporeal shock wave therapy (1000 impulses, energy density 0.06 mJ/mm2, administered 3 times in weekly intervals)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low‐energetic extracorporeal shock wave therapy
Number of subjects: 75
Study: 1442986

Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 43

Group type: COMPARATOR
Intervention: Animal insulin
Number of subjects: 43
Study: 6585839

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 2
Study: 3525431

Group type: EXPERIMENTAL
Intervention: Coenzyme A (2,000 Lipmann U daily) administered intravenously for 20 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sulodexide (300 Lipasemic U daily) administered intravenously for 20 days
Number of subjects: 27
Study: 30204554

Group type: EXPERIMENTAL
Intervention: Active PPARγ agonist pioglitazone (45 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 30
Study: 27904554

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment (four-drug regimen)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (capsules and tablets)
Number of subjects: 49
Study: 25066248

Group type: EXPERIMENTAL
Intervention: Antepartum dalteparin (5000 international units once daily up to 20 weeks' gestation, and twice daily thereafter until at least 37 weeks' gestation)
Number of subjects: 292

Group type: COMPARATOR
Intervention: No antepartum dalteparin (control group)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Antepartum dalteparin
Number of subjects: 292
Study: 24669602

Group type: EXPERIMENTAL
Intervention: Gastric aspiration
Number of subjects: 54

Group type: COMPARATOR
Intervention: No gastric aspiration (Control)
Number of subjects: 54
Study: 20574541

Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine‐pyrimethamine (SP)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 18492125

Group type: EXPERIMENTAL
Intervention: Etravirine alone (100 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ranitidine (150 mg b.i.d. for 11 days) + Etravirine (100 mg on day 8)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Omeprazole (40 mg q.d. for 11 days) + Etravirine (100 mg on day 8)
Number of subjects: 19
Study: 16825031

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl (30 to 180 mg/day)
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1136

Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Number of subjects: 1136
Study: 14688560

Group type: EXPERIMENTAL
Intervention: Height growth velocity
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Weight growth velocity
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Head circumference growth velocity
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Viral load
Number of subjects: 494
Study: 10780128

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Intensive outpatient treatment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard outpatient treatment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 192
Study: 8831956

Group type: EXPERIMENTAL
Intervention: UCS inflation procedure
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 50
Study: 1442677

Group type: EXPERIMENTAL
Intervention: 2 mg triglycyl‐lysin‐vasopressin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40